Andrea Kapinová
Comenius University in Bratislava
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Andrea Kapinová.
International Journal of Experimental Pathology | 2014
Peter Orendáš; Peter Kubatka; Bianka Bojková; Monika Kassayová; Karol Kajo; Desanka Výbohová; Peter Kružliak; Martin Péč; Marian Adamkov; Andrea Kapinová; K. Adamicova; Vladimíra Sadloňová; Martina Chmelová; Nadežda Stollárová
Previous studies in the field of cancer research have suggested a possible role for statins in the reduction of risk in certain malignancies. The purpose of these studies was to examine the chemopreventive effects of pravastatin alone and in combination with pineal hormone melatonin in the N‐methyl‐N‐nitrosourea‐induced mammary carcinogenesis model. Pravastatin was given orally (1 00 mg/kg) and melatonin was added to the water (20 μg/ml). Chemoprevention began seven days prior to carcinogen administration and subsequently continued for 15 weeks until autopsy. At autopsy, mammary tumours were removed and prepared for histopathological and immunohistochemical analysis. Parameters of experimental carcinogenesis, mechanism of action (biomarkers of apoptosis, angiogenesis and proliferation) and side effects after long‐term treatment in animals were assessed. Pravastatin alone suppressed tumour frequency by 20.5% and average tumour volume by 15% compared with controls. Combined administration of the drugs decreased tumour frequency by 69% and lengthened tumour latency by nine days compared with control animals. The ration between high and low grade carcinomas was apparently reduced in both treated groups. The analysis of carcinoma cells showed significant expression increase in caspase‐3 and caspase‐7 after pravastatin treatment; however, combined treatment even more pronounced increase in the expression of both caspases. Regarding VEGFR‐2 expression, a small effect in carcinomas of both treated groups was found. In plasma metabolism evaluation, pravastatin alone significantly decreased levels of glucose and triacylglycerols. Our results suggest a mild anti‐neoplastic effect of pravastatin in this rat mammary gland carcinoma model. Statins co‐administered with other suitable drug (e.g. melatonin) should be further evaluated for tumour‐preventive properties.
Nutrition and Cancer | 2016
Peter Kubatka; Martin Kello; Karol Kajo; Peter Kruzliak; Desanka Výbohová; Karel Šmejkal; Petr Marsik; Anthony Zulli; Gabriela Gönciová; Ján Mojžiš; Andrea Kapinová; Radovan Murín; Martin Péč; Marian Adamkov; Ronald M. Przygodzki
ABSTRACT The effect of dietary administered young barley containing a mixture of phytochemicals to female rats for the prevention of N-methyl-N-nitrosourea-induced mammary carcinogenesis was evaluated. After carcinogen administration (14 wk), mammary tumors were removed and prepared for histopathological and immunohistochemical analysis. Moreover, in vitro evaluation of possible mechanisms in MCF-7 breast cancer cell line was performed. Barley (0.3%) demonstrated mild antitumor effect in mammary carcinogenesis, yet 3% barley did not further improve this effect. Immunohistochemical analysis of rat tumor cells in treated groups showed significant increase in caspase-3 expression and significant reduction in Ki67 expression. In addition, 3% barley significantly decreased dityrosine levels versus control. Barley in higher dose significantly decreased serum low-density lipoprotein-cholesterol in rats. In vitro studies showed that barley significantly decreased survival of MCF-7 cells in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and significantly decreased 5-bromo-20-deoxyuridine incorporation versus control. Barley prevented cell cycle progression and extended incubation with barley showed significant increase in the percentage of annexin V/propidium iodide-positive MCF-7 cells. Our results propose an antitumor effect for the mixture of phytochemicals present in young barley in a breast cancer model.
European Journal of Cancer Prevention | 2013
Peter Kubatka; Nadežda Stollárová; Jozef Škarda; Katarína Žihlavníková; Karol Kajo; Andrea Kapinová; K. Adamicova; Martin Péč; Dusan Dobrota; Bianka Bojková; Monika Kassayová; Peter Orendáš
On the basis of preclinical and clinical evidence, statins lead to risk reduction of several types of neoplasia including breast cancer. This study is the first report on the preventive effects of fluvastatin in experimental breast cancer in vivo. In this experiment, the antineoplastic effects of fluvastatin in the chemoprevention of N-methyl-N-nitrosourea-induced mammary carcinogenesis in female rats were evaluated. The effects of fluvastatin on selected parameters of apoptosis, proliferation, and angiogenesis in mammary tumor cells were determined. The drug was dietary administered at two concentrations of 20 and 200 mg/kg. The experiment was terminated 17 weeks after carcinogen administration; mammary tumors were removed and prepared for histomorphological and immunohistochemical analysis. The basic parameters of experimental carcinogenesis, chosen metabolic variables, and side effects after long-term fluvastatin treatment in animals were assessed. Fluvastatin at higher concentrations suppressed tumor frequency by 63% and tumor incidence by 33% in comparison with the controls. After fluvastatin treatment, immunohistochemical analysis of tumor cells showed a decrease in vascular endothelial growth factor receptor-2 expression by 86% and an increase in caspase-3 by 8.5%. Fluvastatin in both treated groups significantly increased the parameters of serum lipid metabolism and significantly decreased femur compact bone thickness and body weight in animals. Our results suggest that fluvastatin and other statins should be further evaluated for tumor-preventive characteristics.
Biologia | 2015
Andrea Kapinová; Peter Kubatka; Peter Kružliak; Michal Mokáň; Martin Péč; Monika Kassayová; Bianka Bojková; Dusan Dobrota
Abstract On the basis of several preclinical and clinical studies, we have assumed that phytochemicals may play an important role in plasma lipid metabolism. The aim of this study was to evaluate the effects of dietary administered Chlorella pyrenoidosa, young barley and fruit peel polyphenols from Flavin7 on plasma lipid metabolism in breast cancer model in female rats. The phytopharmaceuticals were dietary administered at two different concentrations (0.3% and 3%). The administration of drugs lasted for the whole duration of the experiment (14-15 weeks) until autopsy. At the end of the experiments blood was collected from animals and serum lipid parameters were evaluated. Flavin7 in lower dose significantly decreased LDL-cholesterol and in higher dose significantly decreased triacylglycerol and VLDL-cholesterol levels. Chlorella at the higher dose significantly decreased LDL- and VLDL-cholesterol and triacylglycerol levels. Young barley significantly decreased LDL cholesterol (at the higher dose); on the other hand, a tendency of increased serum triacylglycerol and VLDLcholesterol levels was found (in both doses). Our results pointed to significant beneficial effects of fruit peel polyphenols from Flavin7 and C. pyrenoidosa on plasma lipid metabolism in female rats. Further research is needed to elucidate the health benefits of phytochemicals in whole foods.
Environmental Health and Preventive Medicine | 2018
Andrea Kapinová; Peter Kubatka; O. Golubnitschaja; Martin Kello; Pavol Zubor; Peter Solár; Martin Péč
Cancerous tissue transformation developing usually over years or even decades of life is a highly complex process involving strong stressors damaging DNA, chronic inflammation, comprehensive interaction between relevant molecular pathways, and cellular cross-talk within the neighboring tissues. Only the minor part of all cancer cases are caused by inborn predisposition; the absolute majority carries a sporadic character based on modifiable risk factors which play a central role in cancer prevention. Amongst most promising candidates for dietary supplements are bioactive phytochemicals demonstrating strong anticancer effects. Abundant evidence has been collected for beneficial effects of flavonoids, carotenoids, phenolic acids, and organosulfur compounds affecting a number of cancer-related pathways. Phytochemicals may positively affect processes of cell signaling, cell cycle regulation, oxidative stress response, and inflammation. They can modulate non-coding RNAs, upregulate tumor suppressive miRNAs, and downregulate oncogenic miRNAs that synergically inhibits cancer cell growth and cancer stem cell self-renewal. Potential clinical utility of the phytochemicals is discussed providing examples for chemoprevention against and therapy for human breast cancer. Expert recommendations are provided in the context of preventive medicine.
Biomedicine & Pharmacotherapy | 2018
Andrea Kapinová; Peter Kubatka; Pavol Zubor; Olga Golubnitschaja; Zuzana Danková; Sona Uramova; Ivana Pilchova; Martin Caprnda; Radka Opatrilova; Jan Richnavsky; Peter Kruzliak; Jan Danko
Long non-coding RNAs (lncRNAs) are DNA transcripts longer than 200 nucleotides without protein-coding potential. As they are key regulators of gene expression at chromatic, transcriptional and posttranscriptional level, they play important role in various biological and pathological processes. Dysregulation of lncRNAs has been observed in several diseases including cancer. Breast cancer is heterogeneous disease with many molecular subtypes specific in different prognosis and treatment responses. Hypoxia, a common micro-environmental feature of rapidly growing tumour is associated with metastases, recurrences and resistance to therapy. Aberrant expression of hypoxia related lncRNAs significantly correlates with poor outcomes in cancer patients, as the lncRNAs play an important regulatory role in the breast cancer-cell survival. Thus, a better understanding of lncRNAs role in the hypoxic conditions of breast cancer is crucial for precise understanding of the tumorigenesis, disease features and poor clinical outcome, especially in highly aggressive breast cancer subtypes (HER2-positive and triple-negative types). Moreover, lncRNAs may represent tumour marker predicting prognosis and therapeutic targets improving precise and personalized therapy for better patient´s survival. In this review, we summarize the recent information on lncRNAs in breast cancer with special focus on the hypoxia-responsive lncRNAs and their potential impact on the prognosis, therapy algorithms and individual outcomes. Presented data helps in better understanding of the specific mechanisms predicting new therapeutic agents and strategies for the pharmacological intervention.
General Physiology and Biophysics | 2017
Zuzana Danková; Pavol Zubor; Marian Grendar; Andrea Kapinová; Katarina Zelinova; Marianna Jagelkova; Alexandra Gondova; Karol Dokus; Michal Kalman; Zora Lasabova; Jan Danko
The fibroblast growth factor receptors (FGFRs) and Ras/mitogen activated protein (RAS/MAP) signalling cascades are the main molecular pathways involved in breast carcinogenesis. This study aims to determine the association between FGF10 (rs4415084 C>T), FGFR2 (rs2981582 C>T) and MAP3K1 (rs889312 A>C) gene polymorphisms and breast cancer, to analyse the discriminative ability of each SNP and to test the accuracy of the predictive breast cancer risk model which includes all SNPs. We conducted a case-control study of 170 women (57.06 ± 11.60 years) with histologically confirmed breast cancer and 146 controls (50.24 ± 10.69 years). High resolution melting (HRM) method with Sanger sequencing validation was used in analyses. We have revealed significant association of FGFR2 and MAP3K1 polymorphisms with breast cancer. The odds ratio of FGFR2 T allele was 1.897 (95% CI 1.231-2.936, p = 0.004) and MAP3K1 C allele 1.804 (95% CI 1.151-2.845, p = 0.012). FGFR2 polymorphism achieved the best discriminative ability (41.95%). The Random Forest algorithm selected FGFR2, MAP3K1 and age as important breast cancer predictors. The accuracy of this prediction model approached moderate accuracy (70%), with 35.9% sensitivity and 88.6% specificity.
European Journal of Nutrition | 2016
Peter Kubatka; Andrea Kapinová; Martin Kello; Peter Kruzliak; Karol Kajo; Desanka Výbohová; Silvia Mahmood; Radovan Murín; Tischlerová Viera; Ján Mojžiš; Anthony Zulli; Martin Péč; Marian Adamkov; Monika Kassayová; Bianka Bojková; Nadežda Stollárová; Dusan Dobrota
Nutrition | 2015
Peter Kubatka; Andrea Kapinová; Peter Kružliak; Martin Kello; Desanka Výbohová; Karol Kajo; Miroslav Novák; Martina Chripková; Marian Adamkov; Martin Péč; Ján Mojžiš; Bianka Bojková; Monika Kassayová; Nadežda Stollárová; Dusan Dobrota
Biomedicine & Pharmacotherapy | 2017
Andrea Kapinová; Patrik Stefanicka; Peter Kubatka; Pavol Zubor; Sona Uramova; Martin Kello; Jan Mojzis; Dana Blahútová; Tawar Qaradakhi; Anthony Zulli; Martin Caprnda; Jan Danko; Zora Lasabova; Dietrich Büsselberg; Peter Kruzliak